Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026

Phase 1positiveABI-6250Positive

AI Analysis

Summary

Assembly Biosciences will present positive Phase 1a safety, tolerability and target engagement data for ABI-6250 at AASLD The Liver Meeting 2026, with the pharmacodynamic analysis recognized as a Poster of Distinction.

Clinical Trial Data

Phase

Phase 1a

Primary Endpoint

Met

Outcome Details

Phase 1a safety, tolerability and target engagement data; pharmacodynamic analysis recognized as Poster of Distinction

Importance:5/10

Sentiment:

0.70

Phase 1 datasafetytolerabilitytarget engagementconference presentationAASLD

Related Companies

$ASMB

Read the original article

Published by GlobeNewswire Pharma on October 5, 2026 2:00 PM

Read Original